Dantron

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Dantron
Dantron.svg
1,8-Dihydroxyanthraquinone-3D-balls.png
Clinical data
Routes of
administration
Oral, rectal (enema)
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
NIAID ChemDB
ECHA InfoCard 100.003.794
Chemical and physical data
Formula C14H8O4
Molar mass 240.211 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Dantron (INN), also known as chrysazin or 1,8-dihydroxyanthraquinone, is an organic substance, formally derived from anthraquinone by the replacement of two hydrogen atoms by hydroxyl groups (–OH). It is used in some countries as a stimulant laxative.

It should not be confused with ondansetron, an unrelated drug that was marketed in South Africa under the trade name "Dantron".

Medical uses[edit]

In the USA, dantron is not used because it is considered to be a carcinogen.[1]

In the UK it is considered a possible carcinogen and so its licence is restricted to patients who already have a diagnosis of terminal cancer. It is mainly used in palliative care to counteract the constipating effects of opioids. Its British Approved Name was danthron, but it has now been changed to "dantron", the recommended International Nonproprietary Name.[2]

Dantron has the notable side-effect of causing red-colored urine.

See also[edit]

References[edit]